Trial Review

Technical difficulties have been reported by some users of the search function and is being investigated by technical staff. Thank you for your patience and apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT05608291




Registration number
NCT05608291
Ethics application status
Date submitted
14/10/2022
Date registered
8/11/2022
Date last updated
22/05/2024

Titles & IDs
Public title
A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery
Scientific title
A Phase 3 Trial of Fianlimab (Anti-LAG-3) and Cemiplimab Versus Pembrolizumab in the Adjuvant Setting in Patients With Completely Resected High-risk Melanoma
Secondary ID [1] 0 0
2022-501576-25-00
Secondary ID [2] 0 0
R3767-ONC-2055
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Melanoma 0 0
Condition category
Condition code
Cancer 0 0 0 0
Malignant melanoma

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Fianlimab
Treatment: Drugs - Cemiplimab
Treatment: Drugs - Pembrolizumab
Treatment: Drugs - Placebo

Experimental: Fianlimab HD + Cemiplimab - Patients will be administered one combination dose of fianlimab high dose (HD) and cemiplimab

Experimental: Fianlimab LD + Cemiplimab - Patients will be administered one combination dose of fianlimab low dose (LD) and cemiplimab

Active Comparator: Pembrolizumab - Patients will be administered one dose of pembrolizumab co-infused with saline/dextrose placebo


Treatment: Drugs: Fianlimab
Fianlimab will be administered by intravenous (IV) infusion every (Q) 3 weeks

Treatment: Drugs: Cemiplimab
Cemiplimab will be administered by IV infusion Q 3 weeks

Treatment: Drugs: Pembrolizumab
Pembrolizumab will be administered by IV infusion Q 3 weeks

Treatment: Drugs: Placebo
Matching placebo co-infused with pembrolizumab IV, will be administered by IV infusion Q 3 weeks
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Relapse free survival (RSF)
Timepoint [1] 0 0
Up to 5 Years
Secondary outcome [1] 0 0
Distant metastasis-free survival (DMFS)
Timepoint [1] 0 0
Up to 5 Years
Secondary outcome [2] 0 0
Overall survival (OS)
Timepoint [2] 0 0
Up to 5 Years
Secondary outcome [3] 0 0
Occurrence of treatment-emergent adverse events (TEAEs)
Timepoint [3] 0 0
Up to 5 Years
Secondary outcome [4] 0 0
Occurrence of immune-mediated EAEs (im-EAEs)
Timepoint [4] 0 0
Up to 5 Years
Secondary outcome [5] 0 0
Occurrence of serious adverse events (SAEs)
Timepoint [5] 0 0
Up to 5 Years
Secondary outcome [6] 0 0
Occurrence of adverse events of special interest (AESIs)
Timepoint [6] 0 0
Up to 5 Years
Secondary outcome [7] 0 0
Occurrence of TEAEs resulting in death
Timepoint [7] 0 0
Up to 5 Years
Secondary outcome [8] 0 0
Occurrence of dose-limiting toxicity (DLT)
Timepoint [8] 0 0
Up to 5 Years
Secondary outcome [9] 0 0
Occurrence of interruption or discontinuation of study drug(s) due to TEAE
Timepoint [9] 0 0
Up to 5 Years
Secondary outcome [10] 0 0
Occurrence of laboratory abnormalities
Timepoint [10] 0 0
Up to 5 Years
Secondary outcome [11] 0 0
Concentrations of fianlimab in serum over time
Timepoint [11] 0 0
Up to 5 Years
Secondary outcome [12] 0 0
Concentrations of cemiplimab in serum over time
Timepoint [12] 0 0
Up to 5 Years
Secondary outcome [13] 0 0
Concentration of finalimab anti-drug antibodies (ADA) and neutralizing antibodies
Timepoint [13] 0 0
Up to 5 Years
Secondary outcome [14] 0 0
Concentration of cemiplimab anti-drug antibodies (ADA) and neutralizing antibodies
Timepoint [14] 0 0
Up to 5 Years
Secondary outcome [15] 0 0
Patient report outcomes (PRO) for adults as measured by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Timepoint [15] 0 0
Up to 5 Year
Secondary outcome [16] 0 0
PRO for adults as measured by the European Quality of Life Dimension 5 (EQ-5D-5L)
Timepoint [16] 0 0
Up to 5 Years
Secondary outcome [17] 0 0
PRO for adults as measured by the Functional Assessment of Cancer Therapy (FACT) - melanoma
Timepoint [17] 0 0
Up to 5 Years
Secondary outcome [18] 0 0
PRO for adults as determined by the Patient Global Impressions Scale (PGIS)
Timepoint [18] 0 0
Up to 5 Years
Secondary outcome [19] 0 0
PRO for adults as determined by the Patient Global Impressions of Change Scale (PGIC)
Timepoint [19] 0 0
Up to 5 Years
Secondary outcome [20] 0 0
Time to global health status/quality of life deterioration per EORTC QLQ-C30
Timepoint [20] 0 0
Up to 5 years
Secondary outcome [21] 0 0
Time to physical functioning deterioration per EORTC QLQ-C30
Timepoint [21] 0 0
Up to 5 Years
Secondary outcome [22] 0 0
Time to role functioning deterioration per EORTC QLQ-C30
Timepoint [22] 0 0
Up to 5 Years

Eligibility
Key inclusion criteria
Key

1. All patients must be either stage IIB, IIC, III, or stage IV per American Joint
Committee on Cancer (AJCC) 8th edition and have histologically confirmed melanoma that
is completely surgically resected in order to be eligible as defined by the protocol

2. Complete surgical resection must be performed within 12 weeks prior to randomization,
and enrollment may occur only after satisfactory wound healing from the surgery

3. All patients must have disease-free status documented by a complete physical
examination and imaging studies within 4 weeks prior to randomization, as described in
the protocol

Key
Minimum age
12 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Uveal melanoma

2. Any evidence of residual disease after surgery by imaging, pathology, or cytology.

3. Ongoing or recent (within 2 years) evidence of clinically significant autoimmune
disease that required treatment

4. Uncontrolled infection with human immunodeficiency virus (HIV), hepatitis B virus
(HBV), or hepatitis C (HCV) infection; or diagnosis of immunodeficiency that is
related to, or results in chronic infection, as described in the protocol

5. Another malignancy that is currently progressing or that required active treatment in
the past 5 years, as described in the protocol

6. Participants with a history of myocarditis

7. Adolescent patients (=12 to <18 years old) with body weight <40 kg

Note: Other Protocol Defined Inclusion/ Exclusion Criteria Apply

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
16/01/2023
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
15/02/2030
Actual
Sample size
Target
1530
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,SA,VIC,WA
Recruitment hospital [1] 0 0
Liverpool Hospital (Cancer Therapy Pharmacy) - Liverpool
Recruitment hospital [2] 0 0
Calvary North Adelaid Hospital (HPS Pharmacies) - Adelaide
Recruitment hospital [3] 0 0
Flinders Medical Centre - Bedford Park
Recruitment hospital [4] 0 0
Box Hill Hospital - Box Hill
Recruitment hospital [5] 0 0
Andrew Love Cancer Centre, University Hospital Geelong - Geelong
Recruitment hospital [6] 0 0
Alfred Health - Melbourne
Recruitment hospital [7] 0 0
One Clinical Research - Nedlands
Recruitment postcode(s) [1] 0 0
2170 - Liverpool
Recruitment postcode(s) [2] 0 0
5006 - Adelaide
Recruitment postcode(s) [3] 0 0
5042 - Bedford Park
Recruitment postcode(s) [4] 0 0
3128 - Box Hill
Recruitment postcode(s) [5] 0 0
3220 - Geelong
Recruitment postcode(s) [6] 0 0
3004 - Melbourne
Recruitment postcode(s) [7] 0 0
6009 - Nedlands
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
California
Country [2] 0 0
United States of America
State/province [2] 0 0
Colorado
Country [3] 0 0
United States of America
State/province [3] 0 0
Florida
Country [4] 0 0
United States of America
State/province [4] 0 0
Illinois
Country [5] 0 0
United States of America
State/province [5] 0 0
Massachusetts
Country [6] 0 0
United States of America
State/province [6] 0 0
New Jersey
Country [7] 0 0
United States of America
State/province [7] 0 0
New York
Country [8] 0 0
United States of America
State/province [8] 0 0
North Carolina
Country [9] 0 0
United States of America
State/province [9] 0 0
Ohio
Country [10] 0 0
United States of America
State/province [10] 0 0
Pennsylvania
Country [11] 0 0
United States of America
State/province [11] 0 0
Tennessee
Country [12] 0 0
United States of America
State/province [12] 0 0
Texas
Country [13] 0 0
United States of America
State/province [13] 0 0
Utah
Country [14] 0 0
United States of America
State/province [14] 0 0
Virginia
Country [15] 0 0
Argentina
State/province [15] 0 0
Buenos Aires
Country [16] 0 0
Argentina
State/province [16] 0 0
Rio Negro
Country [17] 0 0
Argentina
State/province [17] 0 0
Santa Fe
Country [18] 0 0
Argentina
State/province [18] 0 0
Tacuman Province
Country [19] 0 0
Belgium
State/province [19] 0 0
East Flanders
Country [20] 0 0
Belgium
State/province [20] 0 0
Region De Bruxelles
Country [21] 0 0
Belgium
State/province [21] 0 0
West-Vlaaderen
Country [22] 0 0
Brazil
State/province [22] 0 0
Minas Geraise
Country [23] 0 0
Brazil
State/province [23] 0 0
Parana
Country [24] 0 0
Brazil
State/province [24] 0 0
Rio De Janeiro
Country [25] 0 0
Brazil
State/province [25] 0 0
Rio Grande Do Sul
Country [26] 0 0
Brazil
State/province [26] 0 0
Santa Catarina
Country [27] 0 0
Brazil
State/province [27] 0 0
Sao Paulo Estado
Country [28] 0 0
Brazil
State/province [28] 0 0
Sao Paulo
Country [29] 0 0
Canada
State/province [29] 0 0
New Brunswick
Country [30] 0 0
Canada
State/province [30] 0 0
Ontario
Country [31] 0 0
Chile
State/province [31] 0 0
Metropolitana De Santiago
Country [32] 0 0
Chile
State/province [32] 0 0
Santiago Region Metropolitana De Santiago
Country [33] 0 0
Chile
State/province [33] 0 0
Valparaiso
Country [34] 0 0
Czechia
State/province [34] 0 0
Bohemia
Country [35] 0 0
Czechia
State/province [35] 0 0
Moravia Region
Country [36] 0 0
Czechia
State/province [36] 0 0
South Moravian
Country [37] 0 0
France
State/province [37] 0 0
Bourgogne-Franche-Comte
Country [38] 0 0
France
State/province [38] 0 0
Bourgogne-Franche-Comté
Country [39] 0 0
France
State/province [39] 0 0
Bourgogne
Country [40] 0 0
France
State/province [40] 0 0
Grenoble
Country [41] 0 0
France
State/province [41] 0 0
Haute-Garonne
Country [42] 0 0
France
State/province [42] 0 0
Ile De France
Country [43] 0 0
France
State/province [43] 0 0
Ile-de-France
Country [44] 0 0
France
State/province [44] 0 0
Nord Deparment
Country [45] 0 0
France
State/province [45] 0 0
Normandy
Country [46] 0 0
France
State/province [46] 0 0
Nouvelle-Aquitaine
Country [47] 0 0
France
State/province [47] 0 0
Occitanie Region
Country [48] 0 0
France
State/province [48] 0 0
Paris
Country [49] 0 0
France
State/province [49] 0 0
Pays De La Loire Région
Country [50] 0 0
France
State/province [50] 0 0
Province Alpes Cote d'Azur
Country [51] 0 0
France
State/province [51] 0 0
Puy-de-Dôme
Country [52] 0 0
France
State/province [52] 0 0
Sarthe
Country [53] 0 0
France
State/province [53] 0 0
Seine Saint Denis
Country [54] 0 0
France
State/province [54] 0 0
Somme
Country [55] 0 0
France
State/province [55] 0 0
Nice
Country [56] 0 0
France
State/province [56] 0 0
Rouen
Country [57] 0 0
Georgia
State/province [57] 0 0
Adjara
Country [58] 0 0
Georgia
State/province [58] 0 0
South Caucasus
Country [59] 0 0
Germany
State/province [59] 0 0
Baden-Wurttemberg
Country [60] 0 0
Germany
State/province [60] 0 0
Bavaria
Country [61] 0 0
Germany
State/province [61] 0 0
Hessen
Country [62] 0 0
Germany
State/province [62] 0 0
Lower Saxony
Country [63] 0 0
Germany
State/province [63] 0 0
Mecklenburg Vorpommern
Country [64] 0 0
Germany
State/province [64] 0 0
North Rhine-Westphalia
Country [65] 0 0
Germany
State/province [65] 0 0
Rhindeland Palatinate
Country [66] 0 0
Germany
State/province [66] 0 0
Sachsen-Anhalt
Country [67] 0 0
Germany
State/province [67] 0 0
Saxony
Country [68] 0 0
Germany
State/province [68] 0 0
Schleswig-Holstein
Country [69] 0 0
Germany
State/province [69] 0 0
Berlin
Country [70] 0 0
Germany
State/province [70] 0 0
Bochum
Country [71] 0 0
Germany
State/province [71] 0 0
Bremen
Country [72] 0 0
Germany
State/province [72] 0 0
Erfurt
Country [73] 0 0
Germany
State/province [73] 0 0
Essen
Country [74] 0 0
Germany
State/province [74] 0 0
Regensburg
Country [75] 0 0
Greece
State/province [75] 0 0
Athens
Country [76] 0 0
Greece
State/province [76] 0 0
Pireas
Country [77] 0 0
Greece
State/province [77] 0 0
Pylaia
Country [78] 0 0
Greece
State/province [78] 0 0
Thessalonili
Country [79] 0 0
Ireland
State/province [79] 0 0
Connacht
Country [80] 0 0
Ireland
State/province [80] 0 0
Dublin
Country [81] 0 0
Ireland
State/province [81] 0 0
Munster
Country [82] 0 0
Israel
State/province [82] 0 0
Northern District
Country [83] 0 0
Israel
State/province [83] 0 0
Tel Aviv
Country [84] 0 0
Israel
State/province [84] 0 0
Jerusalem
Country [85] 0 0
Italy
State/province [85] 0 0
Abruzzo
Country [86] 0 0
Italy
State/province [86] 0 0
Campania
Country [87] 0 0
Italy
State/province [87] 0 0
Friuli-Venezia Giulia
Country [88] 0 0
Italy
State/province [88] 0 0
Lazio
Country [89] 0 0
Italy
State/province [89] 0 0
Lombardy
Country [90] 0 0
Italy
State/province [90] 0 0
Metropolitan City Of Bari
Country [91] 0 0
Italy
State/province [91] 0 0
Piedmont
Country [92] 0 0
Italy
State/province [92] 0 0
Rome Province
Country [93] 0 0
Italy
State/province [93] 0 0
Umbria
Country [94] 0 0
Italy
State/province [94] 0 0
Veneto
Country [95] 0 0
Italy
State/province [95] 0 0
Novara
Country [96] 0 0
Italy
State/province [96] 0 0
Taormina
Country [97] 0 0
Italy
State/province [97] 0 0
Torrette
Country [98] 0 0
Italy
State/province [98] 0 0
Trento
Country [99] 0 0
Mexico
State/province [99] 0 0
Guanajuato
Country [100] 0 0
Mexico
State/province [100] 0 0
Jalisco
Country [101] 0 0
Mexico
State/province [101] 0 0
Nuevo Leon
Country [102] 0 0
Mexico
State/province [102] 0 0
Sinaloa
Country [103] 0 0
Mexico
State/province [103] 0 0
Veracruz Estado
Country [104] 0 0
Mexico
State/province [104] 0 0
Yucatan
Country [105] 0 0
Poland
State/province [105] 0 0
Mazowieckie
Country [106] 0 0
Poland
State/province [106] 0 0
Pomeria
Country [107] 0 0
Poland
State/province [107] 0 0
Pomorskie
Country [108] 0 0
Romania
State/province [108] 0 0
Dolj
Country [109] 0 0
Romania
State/province [109] 0 0
Floresti
Country [110] 0 0
Romania
State/province [110] 0 0
Moldava
Country [111] 0 0
Romania
State/province [111] 0 0
Timis
Country [112] 0 0
Romania
State/province [112] 0 0
Transylvania
Country [113] 0 0
Romania
State/province [113] 0 0
Bucharest
Country [114] 0 0
South Africa
State/province [114] 0 0
Gauteng
Country [115] 0 0
South Africa
State/province [115] 0 0
Western Cape
Country [116] 0 0
Spain
State/province [116] 0 0
Andalucia
Country [117] 0 0
Spain
State/province [117] 0 0
Asturias
Country [118] 0 0
Spain
State/province [118] 0 0
Cantabria
Country [119] 0 0
Spain
State/province [119] 0 0
Catalonia
Country [120] 0 0
Spain
State/province [120] 0 0
Madrid Provincia
Country [121] 0 0
Spain
State/province [121] 0 0
Badalona
Country [122] 0 0
Spain
State/province [122] 0 0
Granada
Country [123] 0 0
Spain
State/province [123] 0 0
Lugo
Country [124] 0 0
Spain
State/province [124] 0 0
Madrid
Country [125] 0 0
Spain
State/province [125] 0 0
Valencia
Country [126] 0 0
Turkey
State/province [126] 0 0
Anatolia
Country [127] 0 0
Turkey
State/province [127] 0 0
Ankara
Country [128] 0 0
Turkey
State/province [128] 0 0
Central Anatolia
Country [129] 0 0
Turkey
State/province [129] 0 0
Cilicia
Country [130] 0 0
Turkey
State/province [130] 0 0
Diyarbakir Province
Country [131] 0 0
Turkey
State/province [131] 0 0
Edime
Country [132] 0 0
Turkey
State/province [132] 0 0
Gaziantep
Country [133] 0 0
Turkey
State/province [133] 0 0
Istanbul Province
Country [134] 0 0
Turkey
State/province [134] 0 0
Istanbul
Country [135] 0 0
Turkey
State/province [135] 0 0
Izmir Province
Country [136] 0 0
Turkey
State/province [136] 0 0
Kocaeli
Country [137] 0 0
United Kingdom
State/province [137] 0 0
Devon
Country [138] 0 0
United Kingdom
State/province [138] 0 0
London
Country [139] 0 0
United Kingdom
State/province [139] 0 0
Lothian
Country [140] 0 0
United Kingdom
State/province [140] 0 0
Somerset
Country [141] 0 0
United Kingdom
State/province [141] 0 0
Manchester

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Regeneron Pharmaceuticals
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This study is researching an experimental drug called REGN3767, also known as fianlimab
(R3767), when combined with another medication called cemiplimab (each individually called a
"study drug" or called "study drugs" when combined) compared with an approved medication
called pembrolizumab.

The objective of this study is to see if the combination of fianlimab and cemiplimab is an
effective treatment compared to pembrolizumab in patients that have had melanoma removal
surgery but are still at high risk for the recurrence of the disease. Pembrolizumab is an
approved treatment in some countries in this clinical setting.

The study is looking at several other research questions, including:

- What side effects may happen from receiving the study drugs.

- How much study drug is in the blood at different times.

- Whether the body makes antibodies against the study drug (which could make the drug less
effective or could lead to side effects). Antibodies are proteins that are naturally
found in the blood stream that fight infections.

- How administering the study drugs might improve quality of life.
Trial website
https://clinicaltrials.gov/ct2/show/NCT05608291
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Clinical Trial Management
Address 0 0
Regeneron Pharmaceuticals
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Clinical Trials Administrator
Address 0 0
Country 0 0
Phone 0 0
844-734-6643
Fax 0 0
Email 0 0
clinicaltrials@regeneron.com
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT05608291